Gene Therapy Research Institute

Gene Therapy Research Institute (GTRI) is a clinical-stage Japanese biotechnology company focused on developing Adeno-Associated Virus (AAV) vector-based gene therapies for intractable neurological disorders. The company's lead candidate, GTR-001, is an AAV-AADC gene therapy designed to treat Parkinson's disease by restoring dopamine production in the brain. GTRI's pipeline also includes programs for Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and Alzheimer's disease, utilizing advanced AAV delivery techniques. The institute leverages proprietary manufacturing processes and strategic clinical collaborations to advance its portfolio of CNS-targeted therapies. It operates its own GMP-compliant facility to ensure high-quality vector production for its clinical programs.